TP53 and Miyoshi myopathy: Fluorescence in situ hybridization (FISH) on CD138-purified plasma cells, minimally targeting 17p/TP53 deletions, t(4;14), t(11;14) and t(14;16) translocations as well as chromosome 1 abnormalities, represents the most widely available and accepted method in clinical practice for SV identification in MM [12,13].